Singapore-based specialty pharmaceutical and consumer healthcare group Hyphens Pharma International Limited (SGX: 1J5) said on Monday that it has licensed the commercialisation of its Cerapro MED Skin Barrier Cream to Swiss cosmetics and pharmaceuticals company Louis Widmer SA under a licensing, supply and commercialisation agreement.

The agreement covers Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands, with a product launch targeted for 2026, and provides Hyphens Pharma with an upfront fee and customary sales royalties.

Cerapro is a patented, skin pH-lowering cream approved as a CE-marked medical device under the European Medical Device Regulation for the treatment of atopic dermatitis, a common form of eczema affecting patients across all age groups.

The product lowers skin pH, and is formulated to help restore the skin barrier and support the skin's antimicrobial defence, offering a novel treatment option for eczema patients.

Under the collaboration, Louis Widmer will commercialise and promote Cerapro to dermatologists and paediatricians in the agreed European markets.